Domača stranIMRN • NASDAQ
add
Immuron Ltd - ADR
Prejšnji trg. dan.
1,93 $
Dnevni razpon
1,81 $ - 2,00 $
Letni razpon
1,59 $ - 5,96 $
Tržna kapitalizacija
17,68 mio. AUD
Povprečni obseg
9,98 tis.
Borzne novice
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (AUD) | jun. 2024info | Sprememba L/L |
|---|---|---|
Prihodek | 1,27 mio. | 108,61 % |
Stroški poslovanja | 2,56 mio. | 79,40 % |
Čisti dohodek | −2,43 mio. | −169,00 % |
Čista dobičkovnost prihodkov | −190,94 | −28,94 % |
Earnings per share | — | — |
EBITDA | −1,68 mio. | −118,52 % |
Efektivna davčna stopnja | — | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (AUD) | jun. 2024info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 11,66 mio. | −32,07 % |
Skupna sredstva | 15,55 mio. | −29,28 % |
Skupne obveznosti | 2,84 mio. | 19,79 % |
Celoten lastniški kapital | 12,71 mio. | — |
Shares outstanding | 228,00 mio. | — |
Razmerje P/B | 32,17 | — |
Donosnost sredstev | −27,02 % | — |
Donosnost kapitala | −32,61 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (AUD) | jun. 2024info | Sprememba L/L |
|---|---|---|
Čisti dohodek | −2,43 mio. | −169,00 % |
Denar iz dejavnosti | −1,94 mio. | −141,79 % |
Denar iz naložb | 87,03 tis. | 1.082,80 % |
Denar iz financiranja | 12,00 tis. | 203,57 % |
Neto sprememba denarnih sredstev | −1,78 mio. | −170,36 % |
Prost denarni tok | −1,03 mio. | −197,20 % |
Vizitka
Immuron is a biotechnology company based in Melbourne, Australia. In 2008, the company changed its name to Immuron Limited, having previously operated as Anadis Limited.
Immuron is focused on antigen-primed and dairy-derived health products. Its proprietary technologies allow for rapid development of polyclonal antibody and other proteins-based solutions for a range of diseases. The company specialises in nutraceutical, pharmaceutical and therapeutic technology products for conditions such as oral and GI mucositis, avian influenza, E. coli travellers' diarrhoea and Anthrax containment.
In 2005, Anadis signed an agreement with Quebec's Baralex Inc. and Valeo Pharma Inc. for the distribution of Travelan, a product made by Anadis for the Canadian market. Wikipedia
Datum ustanovitve
1994
Sedež organizacije
Spletno mesto
Zaposleni
7
